2-(((3-chlorophenyl)amino)(methylthio)methylene)malononitrile | 74906-19-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(((3-chlorophenyl)amino)(methylthio)methylene)malononitrile
• 英文别名: 3-(3-chloroanilino)-2-cyano-3-(methylthio)acrylonitrile；3-(3-chloro-phenylamino)-2-cyano-3-methylmercapto-acrylonitrile；2-[(3-chloroanilino)-methylsulfanylmethylidene]propanedinitrile
• CAS: 74906-19-7
• 化学式: C₁₁H₈ClN₃S
• 分子量: 249.724
• InChiKey: KKVJUYQGOUJUPS-UHFFFAOYSA-N

物化性质

• 沸点：
  359.2±42.0 °C(Predicted)
• 密度：
  1.381±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(((3-chlorophenyl)amino)(methylthio)methylene)malononitrile 在 sodium methylate 作用下， 以 水 为溶剂， 反应 33.25h， 生成 1-benzyl-3-(3-chloro-phenylamino)-4-hydroxy-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors:  4-(Phenylamino)pyrazolo[3,4-d]pyrimidines

  摘要：

  In the course of the random screening of a pool of CIBA chemicals, the two pyrazolopyrimidines 1 and 2 have been identified as fairly potent inhibitors of the EGF-R tyrosine kinase. Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGF-R protein tyrosine kinase (PTK), the class of the pyrazolo[3,4-d]pyrimidines was then optimized in an interactive process leading to a series of 4-(phenylamino)-1H-pyrazolo[3,4-d]-pyrimidines as highly potent inhibitors of the EGF-R tyrosine kinase. The most potent compounds 13, 14, 15, 17, 19, 22, 26, 28, and 30 of this series inhibited the EGF-R PTK with IC50 values below 10 nM. High selectivity toward a panel of nonreceptor tyrosine kinases (c-Src, upsilon-Abl) and serine/threonine kinases (PKC alpha, CDK1) was observed. In cells, EGF-stimulated cellular tyrosine phosphorylation was inhibited by compounds 13, 15, 19, 22, and 23 at IC50 values below 50 nM, whereas PDGF-induced tyrosine phosphorylation was not affected by concentrations up to 10 mu M, thus indicating high selectivity for the inhibition of the ligand-activated EGF-R signal transduction pathway. Compounds 15 and 19 inhibited proliferation of the EGF-dependent MK cell line with IC50 values below 0.5 mu M. In addition, two compounds, 9 and 11, showing satisfactory oral bioavailability in mice after oral administration, exhibited good in vivo efficacy at doses of 12.5 and 50 mg/kg in a nude mouse tumor model using xenografts of the EGF-R overexpressing A431 cell line. From SAR studies, a binding mode for 4-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidines, especially for compound 15, at the ATP-binding site of the EGF-R tyrosine kinase is proposed. 4-(Phenylamino)-1H-pyrazolo[3,4-d]pyrimidines represent a new class of highly potent tyrosine kinase inhibitors which preferentially inhibit the EGF-mediated signal transduction pathway and have the potential for further evaluation as anticancer agents.

  DOI：

  10.1021/jm970124v
• 作为产物：
  描述：

  3-氯苯胺 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 8.5h， 生成 2-(((3-chlorophenyl)amino)(methylthio)methylene)malononitrile
  参考文献：
  名称：

  吡唑并嘧啶：针对鼻和肠病毒衣壳的有效抑制剂。

  摘要：

  当前尚无可用于治疗由肠病毒（EV）引起的急性和慢性疾病的药物，例如普通感冒，脑膜炎，脑炎，肺炎和心肌炎，伴或不伴连续性扩张性心肌病。在这里，我们报告吡唑并嘧啶的发现和表征，吡唑并嘧啶是一类耐受性强且有效的新型EV抑制剂。化合物抑制EV的体外广谱与IC的复制50值之间的0.04和0.64μ中号适用于对pleconaril（一种已知的衣壳结合抑制剂）有抗性的病毒，而不会影响细胞色素P450酶的活性。使用病毒学和遗传学方法，病毒衣壳被确定为最有希望的，口服生物利用的化合物3-（4-三氟甲基苯基）氨基-6-苯基吡唑并[3,4- d ]嘧啶-4-胺（OBR-5 ）的靶标-340）。柯萨奇病毒B3引起的小鼠慢性心肌炎的预防性和治疗性应用都得到了证明。小鼠体内良好的药代动力学，毒理学和药效学特征使OBR-5340成为高度有前途的候选药物，并且正在进行非临床监管计划。

  DOI：

  10.1002/cmdc.201500304

文献信息

• Pyrazole derivatives and processes for the preparation thereof
  申请人：Novartis AG

  公开号：US05981533A1

  公开（公告）日：1999-11-09

  4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula I ##STR1## wherein the symbols are as defined in claim 1, and intermediates for their manufacture are described. The compounds of formula I inhibit especially the tyrosine kinase activity of the receptor for epidermal growth factor and can be used, for example, in the case of epidermal hyperproliferation (psoriasis) and as anti-tumor agents.

  公式I的4-氨基-1H-吡唑并[3,4-d]嘧啶衍生物如下所示：其中符号如权利要求1中所定义，并描述了其制备的中间体。公式I的化合物特别抑制表皮生长因子受体的酪氨酸激酶活性，例如，在表皮过度增生（银屑病）和作为抗肿瘤剂中可以使用。
• [EN] 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE 3,5-DIAMINOPYRAZOLE KINASE
  申请人：AXIKIN PHARMACEUTICALS INC

  公开号：WO2013138613A1

  公开（公告）日：2013-09-19

  Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.

  本文提供了3,5-二氨基吡唑类化合物，例如，Formula IA中的化合物，用于调节COPD激酶活性，并提供了其药物组合物。本文还提供了它们的使用方法，用于治疗、预防或缓解RC激酶介导的疾病、疾病或症状之一。
• Triflic acid-mediated N-heteroannulation of β-anilino-β-(methylthio)acrylonitriles: a facile synthesis of 4-amino-2-(methylthio)quinolines
  作者：Debashruti Bandyopadhyay、Annaram Thirupathi、Divya Radhakrishnan、Adyasha Panigrahi、S. Peruncheralathan

  DOI：10.1039/d1ob01151k

  日期：——

  Various functionalised 4-amino-2-(methylthio)quinolines are synthesised through triflic acid-mediated N-heteroannulation of α-functionalized-β-anilino-β-(methylthio)acrylonitriles for the first time. The N-heteroannulation process is highly chemoselective and has mild reaction conditions. However, this process fails in the absence of the β-methylthio group in the acrylonitriles. In addition, a new

  首次通过三氟甲磺酸介导的α-功能化-β-苯胺基-β-(甲硫基)丙烯腈的N-杂环化合成了各种功能化的4-氨基-2-(甲硫基)喹啉。N-杂环化过程具有高度的化学选择性并且具有温和的反应条件。然而，该方法在丙烯腈中不存在 β-甲硫基的情况下失败。此外，还证明了一种新的双 N-杂环化工艺可以从非杂环前体合成吲哚[3,2- c ]喹啉。天然产物异隐脑油由无环前体分四步合成。
• 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS
  申请人：RAAUM Erik Dean

  公开号：US20130274227A1

  公开（公告）日：2013-10-17

  Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.

  本文提供了3,5-二氨基吡唑，例如式IA的化合物，用于调节COPD调节激酶活性及其药物组成物。本文还提供了使用这些化合物治疗、预防或改善RC激酶介导的疾病、疾病或症状的方法。
• 3,5-diaminopyrazole kinase inhibitors
  申请人：Axikin Pharmaceuticals, Inc.

  公开号：US08916555B2

  公开（公告）日：2014-12-23

  Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.

  本文提供了3,5-二氨基吡唑，例如，公式IA的化合物，用于调节调节性慢性阻塞性肺病激酶活性及其制药组合物。本文还提供了使用它们治疗、预防或改善RC激酶介导的紊乱、疾病或症状的方法。